NeuroBo Pharmaceuticals Reports IND Submission to the US FDA for Conducting P-I Study of DA-1726 to Treat Obesity
Shots:
- The P-I study will assess the safety, tolerability, and PK/PD of single and multiple ascending doses of DA-1726 in obese & healthy subjects. Part 1 enrolls ~45 individuals for SAD study, while part 2 involves a MAD study in ~36 participants, receiving DA-1726 (Q4W) or PBO
- The 1EPs includes safety and tolerability while 2EPs involve PK of DA-1726 through serum concentrations over time and metabolite profiling, particularly at the highest doses. Exploratory endpoints focus on the impact of DA-1726 on metabolic and cardiac indicators, fasting lipid levels, body weight, waist circumference and BMI
- DA-1726 (QW, SC), is a novel oxyntomodulin (OXM) analogue and GLP1R/GCGR dual agonist developed for the treatment of obesity and NASH
Ref: NeuroBo | Image: NeuroBo
Related News:- NeuroBo’s DA-1241 Receives the US FDA’s IND Clearance to Initiate the P-IIa Clinical Trial for Nonalcoholic Steatohepatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
